Articles On Imugene (ASX:IMU)

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

The ASX200 chalked up another day of gains in Thursday trade, and once again it was resources leading the way. The ASX200 Materials index posted a solid 1.51% gain, and has now risen by at least 1% on five of the last seven trading days. Pr...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.45% to 7,413.6 points. Four ASX shares that are failing to follow the market higher today are...

Investor funds continue flowing into ASX listed biotechnology shares this year, with a total of almost $485 million of capital raised this year to date. Adding the flurry of initial public offerings (IPO) undertaken in the biotech domain,...

The biotech’s multi-million-dollar capital raise will support development opportunities across its clinical portfolio over the next four years.

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The ASX tech sector succumbed to the latest selloff in tech equities globally. dragging the rest of the bourse down with it. The ASX 200 retreated 0.7% to close at 7,379 points while the ASX Emerging Companies Index lost 1.06%, closing at 2...

The ASX 200 touched intraday record highs, but could not hold on and closed the day just shy of its all time high. The benchmark index finished 0.46% higher at 7,428, and is now on track to finish July on a 10-month winning streak. Six out...

Securities will remain halted until Thursday, July 29, 2021, or when an announcement is released to the market.

Bell Potter is in the market raising capital for oncolytic immuno-oncology biotech Imugene, which is chaired by Viralytics’ Paul Hopper.

ShareCafeAustralia… One Hour In… ASX200 up 20 ASX200 up 20 points (+0.3%) to 7414.   BlueScope (+2.6%); cracking result.  Said 2H earnings beat guidance as all segments delivered better results than FY20.  Highest profit in 19 years. Imuge...

Local stocks continued to edge higher to end the week, although there was a notable tone of caution compared to the previous three days. The ASX200 finished almost flat at 0.11%, only dragged into the green by the Consumer Staples index (co...

In late afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a small decline. At the time of writing, the benchmark index is down slightly to 7,385.7 points. Four ASX shares that are falling more than mos...

The clinical-stage immuno-oncology company has progressed work across its cancer therapy candidates across the 2021 financial year’s final quarter.

After a rough couple of days, local stocks got back in the saddle on Wednesday as most large cap sectors finished in positive territory. There was no clear standout on the day, with resources and materials both finishing more than 1% higher...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Most ASX large cap sectors finished in the red today, in a topsy-turvy session which saw the ASX200 fall sharply at the open then claw back ground, before losing steam into the close of trade. Yesterday’s rotation out of large cap mining &a...

The ASX 200 edged 0.26% lower after trading flat at lunch time, despite stronger than expected employment numbers. All sectors were in the red, except for Utilities and Materials. Australia’s unemployment rate fell to 4.9%, with 29,100 jobs...

The ASX 200 finished higher by 0.37% today, with the Tech sector the only sector in the red, falling almost 3%. Buy-now-pay-later  (BNPL) headlined today’s trading, with the likes of ASX BNPL stocks such as Afterpay (ASX:APT), Zip Co (ASX:Z...

Healthcare is a constantly changing industry in which you may be asking yourself if your investments are up to date. While the healthcare sector underperformed the S&P/ASX 200 Index (ASX: XJO) in FY21, there were still some ASX-listed...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Imugene is a clinical-stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.

As we’ve covered extensively on the Fool over the past week, the S&P/ASX 200 Index (ASX: XJO) had a very successful year over the last financial year that has just passed us by. Over FY2021, the ASX 200 managed to add a very healthy 24...

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on track to end the week on a solid note. At the time of writing, the benchmark index is up 0.4% to 7,295.1 points. Four ASX shares that are climbing more than most today are list...

The S&P/ASX 200 Index (ASX: XJO) has just finished up one of its best financial years ever. As of market close on 30 June (Wednesday evening), the ASX 200 had managed to finish 24% higher than where it was at the end of FY2020 last yea...

Imugene managing director and chief executive officer Leslie Chong called the approval a “major milestone” for the company as it prepares to commence a phase one trial into metastatic, triple-negative breast cancer with its CHECKvacc drug c...

The Imugene Limited (ASX: IMU) share price is on course to end the week on a positive note. In morning trade, the clinical stage immuno-oncology company’s shares are up 8.5% to 38 cents. This latest gain means the Imugene share price is no...

Wall Street higher as US jobless claims plunged All the three major US benchmarks rose overnight, after US jobless claims fell to a new pandemic low. The Dow Jones rose by 0.38%, the S&P 500 by 0.52% to a fresh record high, while tech-f...

In FY21 the ASX 200 returned over 20 per cent but the 100 best performing ASX stocks all gained over 390 per cent and made an average gain of 821 per cent. Stockhead has compiled a list (see below) of the 100 best performing ASX stocks base...

Shares in ASX biotech companies Anteotech Ltd (ASX: ADO), Imugene Ltd (ASX: IMU) and Little Green Pharma Ltd (ASX: LGP) have all posted exciting gains over the past 12 months. Let’s have a look at the share price performance and recent ne...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week As we appro...

ShareCafeHidden Gems Webinar Recap: RAC, IMU, AUA & BRN Catch up on the full webinar with presentations from Race Oncology (ASX:RAC), Imugene (ASX:IMU), Auderea (ASX:AUA) & Brainchip (ASX: BRN). Hidden Gems Webinar Recap: RAC, IM...

ShareCafeA clinical stage immuno-oncology company Imugene (ASX: IMU) – Hidden Gems Webinar. Presenter – Leslie Chong – CEO & Managing Director – Imugene is a clinical stage immuno-oncology company developing a range of new treatments t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Shares in Imugene Limited (ASX: IMU) continue to be among the most traded shares on the market. Unfortunately for investors, the Immugene share price has been on a heavy losing streak this week, falling 14% in the last 5 days. Imugene is...

The company believes new chief business officer Dr Monil Shah will make a valuable contribution to advance its immuno-oncology programs.

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

The S&P/ASX 200 Index (ASX: XJO) has slipped today after a strong initial push into positive territory. At the time of writing, the ASX 200 is down 0.25% to 7,274.5 points. Let’s take a look at some of the ASX 200 shares that are being...

The S&P/ASX 200 Index (ASX: XJO) had a rather flat day today. The index finished up 0.15% at 7,292 points, well under its new all-time high of 7,315 points that we saw this morning. Let’s take a look at which ASX 200 shares were among...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

It has been a very volatile day for the S&P/ASX 200 Index (ASX: XJO) on Tuesday. However, in afternoon trade, things are looking positive and the index is up 0.2% to 7,294.8points. Four ASX shares that have failed to follow the market...

Last month, the ASX finally reached its pre-pandemic high, went in circles for a couple of weeks then reached it again. What else happened in May? Well, the phase “To the moon” obtained its traditional meaning once more. While the phase has...

The most notable directors trade over $100,000 in the last fortnight was a $4 million trade by Yaniv Meydan from Openpay (ASX:OPY). Meydan, who is based in Israel and whose family vehicle is one of Openpay’s largest shareholders, chipped in...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

By combining its cancer-killing virus with CAR T therapy, Imugene hopes to destroy solid tumours.

The Imugene Limited (ASX: IMU) share price has taken a large hit today. Shares were down over 30% earlier today, but have since recovered and are now trading 12% lower from yesterday’s close. Still, today’s dip isn’t too bad considering how...

ShareCafeAustralia…1 hour in… ASX200 up 14 ASX200 up 14 points (0.2%) to 7107.   AMP (+4.4%); is being sued by ASIC for “unconscionable behaviour” uncovered by the Hayne royal commission 3 years ago.  They were charging dead people.  AMP s...